Early Insulin Therapy and Development of ARDS

早期胰岛素治疗和 ARDS 的发展

基本信息

项目摘要

DESCRIPTION (provided by applicant): There has been relatively little focus on the prevention of Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS). Recently, intensive insulin therapy (NT) have been shown to decrease morbidity and/or mortality in critically ill patients with prolonged intensive care unit (ICU) stays, but the utility of NT to protect against early critical illness events such as ALI/ARDS is unknown. The broad objective of this proposal is to assess the potential of early IIT to prevent ALI/ARDS in at-risk populations. In Aim #1, the association between early insulin therapy and development of ARDS will be examined in a retrospective nested case control study based on the Molecular Epidemiology of ARDS, a large prospective study of patients at risk for ARDS. However, any intervention to prevent ALI/ARDS must occur early, preferably prior to ICU admission, since 38% of ARDS patients fulfill ARDS criteria on the day of ICU admission. Thus in Aim #2, in a randomized control trial, the potential of early IIT initiated in the Emergency Department (ED) to reduce lung injury and modulate mediators implicated in sepsis-related ALI/ARDS will be examined. The method of propensity score analyses and multivariate logistic regression models will be used to account for potential confounders in Aim #1. In Aim #2, lung injury as measured by the Murray Lung Injury Score (LIS) will be recorded serially in the first week of sepsis. In addition, blood samples will be collected from patients with severe sepsis on admission to the ED and on Day 1 and 3 of the study and plasma levels of free fatty acids, tumor necrosis factor-a, interleukin-6 and Von Willebrand Factor antigen will be determined by liquid and gas chromatography and by ELISA. Analyses of covariance will be used to compare the change in LIS and plasma levels over time between patients randomized to receive early IIT in the ED versus the standard ICU group who receive IIT 48 hours after ICU admission. This proposal has significant health relatedness to the NHLBI's mission and relevance to public health. ALI/ARDS is a devastating form of lung injury with significant mortality, morbidity, and health care costs. Any intervention that can decrease the incidence of ALI/ARDS will have a significant epidemiologic impact in lives saved and morbidity averted.
描述(由申请人提供):对急性肺损伤/急性呼吸窘迫综合征(ALI/ARDS)的预防研究相对较少。最近,强化胰岛素治疗(NT)被证明可以降低重症患者的发病率和/或死亡率,但NT对预防早期危重疾病事件(如ALI/ARDS)的有效性尚不清楚。这项建议的广泛目标是评估早期IIT预防高危人群ALI/ARDS的潜力。在目标1中,早期胰岛素治疗和ARDS发展之间的联系将在一项基于ARDS分子流行病学的回溯性嵌套病例对照研究中进行检验,这是一项对有ARDS风险的患者进行的大型前瞻性研究。然而,任何预防ALI/ARDS的干预措施都必须及早进行,最好是在ICU入院之前,因为38%的ARDS患者在入院当天符合ARDS标准。因此,在AIM#2中,在一项随机对照试验中,将研究急诊科(ED)早期IIT在减少肺损伤和调节与脓毒症相关的ALI/ARDS相关的介质方面的潜力。在AIM#1中,将使用倾向评分分析和多变量Logistic回归模型来解释潜在的混杂因素。在AIM#2中,将在脓毒症的第一周连续记录以Murray肺损伤评分(LIS)衡量的肺损伤。此外,严重败血症患者在入院时、研究的第一天和第三天的血液样本将被采集,血浆中游离脂肪酸、肿瘤坏死因子-a、白细胞介素6和血管性血友病因子抗原的水平将通过液、气相色谱和酶联免疫吸附试验进行检测。协方差分析将用于比较在急诊室接受早期IIT的随机患者和在ICU入院48小时后接受IIT的标准ICU组之间LIS和血浆水平随时间的变化。这项提案与NHLBI的使命和公共卫生相关,具有重大的健康相关性。ALI/ARDS是一种毁灭性的肺损伤形式,具有显著的死亡率、发病率和医疗费用。任何能够降低ALI/ARDS发生率的干预措施都将在挽救生命和避免发病率方面产生重大的流行病学影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHELLE Ng GONG其他文献

MICHELLE Ng GONG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHELLE Ng GONG', 18)}}的其他基金

TREAT ECARDS: Translating Evidence into Action: Electronic Clinical Decision Support in ARDS
TREAT ECARDS:将证据转化为行动:ARDS 中的电子临床决策支持
  • 批准号:
    9763432
  • 财政年份:
    2018
  • 资助金额:
    $ 48.92万
  • 项目类别:
Digital Implementation Intervention Trials in Acute Lung Care (DIGITAL-C) Network Planning
急性肺护理数字化实施干预试验 (DIGITAL-C) 网络规划
  • 批准号:
    9756472
  • 财政年份:
    2018
  • 资助金额:
    $ 48.92万
  • 项目类别:
Utilizing Innovative Technology To Improve Compliance With Patient Elevation Guidelines – The Impact Of Angulus On Adherence To The Evidence-Based VAP-Prevention Bundle
利用创新技术提高患者抬高指南的合规性 — Angulus 对遵守循证 VAP 预防捆绑包的影响
  • 批准号:
    9139729
  • 财政年份:
    2016
  • 资助金额:
    $ 48.92万
  • 项目类别:
Einstein PETAL: Clinical Center for the PETAL Network
爱因斯坦 PETAL:PETAL 网络临床中心
  • 批准号:
    9172481
  • 财政年份:
    2014
  • 资助金额:
    $ 48.92万
  • 项目类别:
Einstein PETAL: Clinical Center for the PETAL Network
爱因斯坦 PETAL:PETAL 网络临床中心
  • 批准号:
    8704533
  • 财政年份:
    2014
  • 资助金额:
    $ 48.92万
  • 项目类别:
Einstein PETAL: Clinical Center for the PETAL Network
爱因斯坦 PETAL:PETAL 网络临床中心
  • 批准号:
    9062498
  • 财政年份:
    2014
  • 资助金额:
    $ 48.92万
  • 项目类别:
Early Insulin Therapy and Development of ARDS
早期胰岛素治疗和 ARDS 的发展
  • 批准号:
    7491770
  • 财政年份:
    2007
  • 资助金额:
    $ 48.92万
  • 项目类别:
Early Insulin Therapy and Development of ARDS
早期胰岛素治疗和 ARDS 的发展
  • 批准号:
    7866687
  • 财政年份:
    2007
  • 资助金额:
    $ 48.92万
  • 项目类别:
Early Insulin Therapy and Development of ARDS
早期胰岛素治疗和 ARDS 的发展
  • 批准号:
    8057652
  • 财政年份:
    2007
  • 资助金额:
    $ 48.92万
  • 项目类别:
Surrogate Consent in Research
研究中的替代同意书
  • 批准号:
    7868027
  • 财政年份:
    2006
  • 资助金额:
    $ 48.92万
  • 项目类别:

相似海外基金

Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 48.92万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
  • 批准号:
    10100360
  • 财政年份:
    2024
  • 资助金额:
    $ 48.92万
  • 项目类别:
    Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
  • 批准号:
    24K04974
  • 财政年份:
    2024
  • 资助金额:
    $ 48.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
  • 批准号:
    23K01686
  • 财政年份:
    2023
  • 资助金额:
    $ 48.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
  • 批准号:
    23K01692
  • 财政年份:
    2023
  • 资助金额:
    $ 48.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
  • 批准号:
    23K01695
  • 财政年份:
    2023
  • 资助金额:
    $ 48.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
  • 批准号:
    23K01713
  • 财政年份:
    2023
  • 资助金额:
    $ 48.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
  • 批准号:
    2312319
  • 财政年份:
    2023
  • 资助金额:
    $ 48.92万
  • 项目类别:
    Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
  • 批准号:
    23K01715
  • 财政年份:
    2023
  • 资助金额:
    $ 48.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
  • 批准号:
    10585388
  • 财政年份:
    2023
  • 资助金额:
    $ 48.92万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了